Navin Tekwani, MD
Ophthalmology · Saint Louis, MONPI 1538143805
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,269 of the $33,660 with a category attached, or 63.2%. 38 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 24.4% of the total. Reporting peaked in 2019 at $12,251 and has fallen 76.0% since, to $2,935 in 2025. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 603 payments — averaging $55.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$8K
- Alcon$6K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$4K
- AbbVie$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- Bausch & Lomb Americas Inc.$2K
- plus $9K from 32 others
Across 180 payments — averaging $5264.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$233K
- AbbVie$220K
- Johnson & Johnson Surgical Vision, Inc.$191K
- Novartis$59K
- Glaukos Corporation$48K
- Alcon Research LLC$46K
- plus $150K from 8 others
What the payments were for
- Consulting fees$7002%
- Speaking & faculty fees$10,62632%
- Travel & lodging$9813%
- Food & beverage$21,26963%
- Gifts$840%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$7,524
- VYZULTA$2,835
- Rhopressa$2,682
- Clareon$895
- RXSIGHT CONTACT LENS$746
- RXSIGHT INJECTOR CARTRIDGE$746
- RXSIGHT INJECTOR HANDPIECE$746
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$746
- DEXTENZA$739
- Tecnis IOL$719
- LIGHT ADJUSTABLE LENS (LAL)$626
- BROMSITE$625
- DURYSTA$611
- Centurion$606
- Kahook Dual Blade$500
- Streamline Surgical System$500
- Ahmed Glaucoma Valve$500
- STELLARIS$478
- enVista MX60 IOL$469
- Tecnis Multifocal Family of 1-piece IOLS$458
How this compares
$33,660 in reported general payments places this provider in the 90th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 358 | $202,475 |
| RestasisCyclosporine | 55 | $58,481 |
| XiidraLifitegrast | 40 | $47,411 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 139 | $36,572 |
| Cyclosporine | 31 | $22,291 |
| RocklatanNetarsudil Mesylat/Latanoprost | 22 | $20,832 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $19,317 |
| Travoprost | 81 | $13,956 |
| Latanoprost | 1,054 | $11,973 |
| VyzultaLatanoprostene Bunod | 17 | $7,863 |
| Brimonidine Tartrate | 66 | $6,889 |
| Prednisolone Acetate | 180 | $6,585 |
| Loteprednol Etabonate | 33 | $5,719 |
| Alphagan PBrimonidine Tartrate | 17 | $5,124 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $4,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $3,107 | $285,396471 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,814 | $55,27557 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $8,227 | $20,83222 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $4,309 | $5,71933 claims |
| AlconSimbrinza | $5,565 | $4,56817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Saint Louis
- Ranjan MalhotraSaint Louis$809K
- Gregg BerdySaint Louis$360K
- Rajendra ApteSaint Louis$112K
- Ian PithaSaint Louis$85K
- Senthil KrishnasamySaint Louis$46K
- Steven LeeSaint Louis$33K
- John GalanisSaint Louis$20K
- Bruce CohenSaint Louis$11K
- Waseem AnsariSaint Louis$9K
- Sean EdelsteinSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.